vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and EVI INDUSTRIES, INC. (EVI). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $115.3M, roughly 1.5× EVI INDUSTRIES, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 24.4%). Over the past eight quarters, EVI INDUSTRIES, INC.'s revenue compounded faster (17.2% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

EVI Industries, Inc. is a leading distributor of commercial laundry, dry cleaning, and garment care equipment, as well as related parts and supplies. It primarily serves commercial customers across North America, including laundromats, hospitality businesses, healthcare facilities, and multi-family housing properties, offering installation, maintenance and after-sales support services.

ESPR vs EVI — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.5× larger
ESPR
$168.4M
$115.3M
EVI
Growing faster (revenue YoY)
ESPR
ESPR
+119.4% gap
ESPR
143.7%
24.4%
EVI
Faster 2-yr revenue CAGR
EVI
EVI
Annualised
EVI
17.2%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ESPR
ESPR
EVI
EVI
Revenue
$168.4M
$115.3M
Net Profit
$2.4M
Gross Margin
30.8%
Operating Margin
50.6%
3.7%
Net Margin
2.1%
Revenue YoY
143.7%
24.4%
Net Profit YoY
109.9%
EPS (diluted)
$0.32
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
EVI
EVI
Q4 25
$168.4M
$115.3M
Q3 25
$87.3M
$108.3M
Q2 25
$82.4M
$110.0M
Q1 25
$65.0M
$93.5M
Q4 24
$69.1M
$92.7M
Q3 24
$51.6M
$93.6M
Q2 24
$73.8M
$90.1M
Q1 24
$137.7M
$84.0M
Net Profit
ESPR
ESPR
EVI
EVI
Q4 25
$2.4M
Q3 25
$-31.3M
$1.8M
Q2 25
$-12.7M
$2.1M
Q1 25
$-40.5M
$1.0M
Q4 24
$1.1M
Q3 24
$-29.5M
$3.2M
Q2 24
$-61.9M
$2.1M
Q1 24
$61.0M
$956.0K
Gross Margin
ESPR
ESPR
EVI
EVI
Q4 25
30.8%
Q3 25
31.3%
Q2 25
30.8%
Q1 25
30.0%
Q4 24
29.7%
Q3 24
30.8%
Q2 24
30.4%
Q1 24
30.7%
Operating Margin
ESPR
ESPR
EVI
EVI
Q4 25
50.6%
3.7%
Q3 25
-11.4%
3.3%
Q2 25
8.6%
3.7%
Q1 25
-34.0%
2.4%
Q4 24
-6.4%
2.6%
Q3 24
-31.0%
5.3%
Q2 24
3.5%
4.1%
Q1 24
52.5%
2.9%
Net Margin
ESPR
ESPR
EVI
EVI
Q4 25
2.1%
Q3 25
-35.9%
1.7%
Q2 25
-15.4%
1.9%
Q1 25
-62.2%
1.1%
Q4 24
1.2%
Q3 24
-57.2%
3.5%
Q2 24
-83.9%
2.3%
Q1 24
44.3%
1.1%
EPS (diluted)
ESPR
ESPR
EVI
EVI
Q4 25
$0.32
$0.15
Q3 25
$-0.16
$0.11
Q2 25
$-0.06
$0.14
Q1 25
$-0.21
$0.07
Q4 24
$-0.14
$0.07
Q3 24
$-0.15
$0.21
Q2 24
$-0.33
$0.13
Q1 24
$0.34
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
EVI
EVI
Cash + ST InvestmentsLiquidity on hand
$167.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$144.0M
Total Assets
$465.9M
$315.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
EVI
EVI
Q4 25
$167.9M
Q3 25
$92.4M
$4.7M
Q2 25
$86.1M
$8.9M
Q1 25
$114.6M
$5.9M
Q4 24
$144.8M
$3.9M
Q3 24
$144.7M
$4.4M
Q2 24
$189.3M
$4.6M
Q1 24
$226.6M
$3.3M
Total Debt
ESPR
ESPR
EVI
EVI
Q4 25
Q3 25
Q2 25
Q1 25
$24.0M
Q4 24
$27.9M
Q3 24
$19.9M
Q2 24
$12.9M
Q1 24
$21.9M
Stockholders' Equity
ESPR
ESPR
EVI
EVI
Q4 25
$-302.0M
$144.0M
Q3 25
$-451.4M
$140.8M
Q2 25
$-433.5M
$143.5M
Q1 25
$-426.2M
$140.2M
Q4 24
$-388.7M
$138.0M
Q3 24
$-370.2M
$136.1M
Q2 24
$-344.2M
$136.6M
Q1 24
$-294.3M
$133.5M
Total Assets
ESPR
ESPR
EVI
EVI
Q4 25
$465.9M
$315.6M
Q3 25
$364.0M
$321.8M
Q2 25
$347.1M
$307.0M
Q1 25
$324.0M
$251.8M
Q4 24
$343.8M
$248.8M
Q3 24
$314.1M
$245.5M
Q2 24
$352.3M
$230.7M
Q1 24
$373.1M
$239.3M
Debt / Equity
ESPR
ESPR
EVI
EVI
Q4 25
Q3 25
Q2 25
Q1 25
0.17×
Q4 24
0.20×
Q3 24
0.15×
Q2 24
0.09×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
EVI
EVI
Operating Cash FlowLast quarter
$45.2M
$4.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.70×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
EVI
EVI
Q4 25
$45.2M
$4.0M
Q3 25
$-4.3M
$1.0M
Q2 25
$-31.4M
$9.9M
Q1 25
$-22.6M
$9.1M
Q4 24
$-35.0M
$2.0M
Q3 24
$-35.3M
$207.0K
Q2 24
$-7.2M
$12.4M
Q1 24
$53.8M
$9.4M
Free Cash Flow
ESPR
ESPR
EVI
EVI
Q4 25
Q3 25
$-890.0K
Q2 25
$8.2M
Q1 25
$8.1M
Q4 24
$1.1M
Q3 24
$-35.5M
$-1.0M
Q2 24
$-7.3M
$11.2M
Q1 24
$53.8M
$8.1M
FCF Margin
ESPR
ESPR
EVI
EVI
Q4 25
Q3 25
-0.8%
Q2 25
7.5%
Q1 25
8.7%
Q4 24
1.2%
Q3 24
-68.7%
-1.1%
Q2 24
-9.9%
12.4%
Q1 24
39.0%
9.7%
Capex Intensity
ESPR
ESPR
EVI
EVI
Q4 25
0.0%
Q3 25
0.0%
1.8%
Q2 25
0.0%
1.5%
Q1 25
0.0%
1.1%
Q4 24
0.0%
0.9%
Q3 24
0.3%
1.3%
Q2 24
0.1%
1.3%
Q1 24
0.1%
1.5%
Cash Conversion
ESPR
ESPR
EVI
EVI
Q4 25
1.70×
Q3 25
0.55×
Q2 25
4.74×
Q1 25
8.79×
Q4 24
1.74×
Q3 24
0.06×
Q2 24
5.99×
Q1 24
0.88×
9.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

EVI
EVI

Segment breakdown not available.

Related Comparisons